Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5.

Date publication

octobre 2025

Journal

JTO clinical and research reports

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François

Tous les auteurs :
Gazzah A, Ricordel C, Italiano A, Cho BC, Calvo E, Kim DW, Helissey C, Kim JS, Villar MV, Ghiringhelli F, Moreno V, Cousin S, Paz-Ares L, Fagniez N, Chadjaa M, Bauchet AL, Soufflet C, Masson N, Barlesi F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41031047

Résumé

Tusamitamab ravtansine is an antibody-drug conjugate targeting cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) with a maytansinoid payload, DM4. This phase 1b dose-expansion study (NCT02187848) evaluated its safety, pharmacokinetics, and preliminary antitumor activity in patients with nonsquamous NSCLC (NSq NSCLC).

Mots clés

Antibody-drug conjugate, Carcinoembryonic antigen-related cell adhesion molecule 5, Non–small cell lung cancer, Phase 1 study, Tusamitamab ravtansine

Référence

JTO Clin Res Rep. 2025 10;6(10):100844